V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003376 | 210010552 | 1.52 | 78 | Adjuvant (A) | 2020-03-26 | 2020-06-01 | Capecitabine | 02 | N | CAPECITABINE | 101648428 |
| 210003379 | 210010553 | 1.56 | 80.5 | Adjuvant (A) | 2016-09-24 | 2017-04-30 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101641620 |
| 210003381 | 210010555 | null | null | null | null | 2018-06-03 | Carboplatin AUC 6 - 10 | 02 | null | CARBOPLATIN | 101838247 |
| 210003383 | 210010556 | 1.69 | 73 | Palliative (P) | 2021-01-17 | 2021-02-27 | Carboplatin AUC 6 - 10 | 02 | N | CARBOPLATIN | 101405068 |
| 210003389 | 210010558 | 1.7 | 105.6 | Palliative (P) | 2017-04-06 | 2017-04-14 | null | 02 | N | PALBOCICLIB | 100808778 |
| 210003391 | 210010559 | 1.53 | 81.3 | null | 2019-01-16 | 2019-01-16 | EC | null | null | EC | 100277944 |
| 210003393 | 210010561 | 1.63 | 67.4 | Adjuvant (A) | 2016-11-14 | 2017-02-24 | null | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 101536249 |
| 210003395 | 210010562 | 1.55 | 56.5 | Palliative (P) | 2020-04-26 | 2020-04-26 | null | 02 | N | SACITUZUMAB GOVITECAN | 100942361 |
| 210003396 | 210010563 | 1.58 | null | Neo-adjuvant (N) | 2018-03-31 | 2018-07-21 | Capecitabine | 02 | N | CAPECITABINE | 101333374 |
| 210003403 | 210010567 | 1.64 | 63.5 | Neo-adjuvant (N) | 2021-08-26 | 2021-11-01 | Capecitabine | 02 | N | CAPECITABINE | 100277269 |
| 210003407 | 210010570 | 1.57 | 79.35 | Curative (C) | 2020-07-08 | 2020-10-11 | Capecitabine | 02 | N | CAPECITABINE | 101465817 |
| 210003410 | 210010571 | 1.62 | 85.2 | null | 2017-04-29 | 2017-04-30 | null | null | null | CAPECITABINE | 100876739 |
| 210003412 | 210010573 | 1.58 | 76 | null | 2016-11-09 | 2017-01-12 | Letrozole + Palbociclib | 02 | null | LETROZOLE + PALBOCICLIB | 101673507 |
| 210003416 | 210010575 | 1.6 | 65.2 | null | 2018-06-21 | 2020-01-11 | null | 02 | null | ROSCO TRIAL | 101247313 |
| 210003417 | 210010576 | 1.57 | 55.05 | Adjuvant (A) | 2020-03-25 | 2020-04-04 | Bevacizumab | 02 | N | EC | 100638452 |
| 210003418 | 210010577 | 1.71 | 52.4 | Adjuvant (A) | 2016-07-29 | 2017-01-10 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100692735 |
| 210003424 | 210010581 | 1.6 | 81 | Adjuvant (A) | 2019-03-13 | 2019-03-26 | EC | N | N | EC | 100219252 |
| 210003426 | 210010583 | 1.6 | 78.1 | null | 2018-05-04 | 2018-05-24 | GEMCARBO | 02 | null | CARBOPLATIN + GEMCITABINE | 101846842 |
| 210003429 | 210010586 | null | 87.5 | null | 2017-01-17 | 2017-01-31 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100147183 |
| 210003430 | 210010587 | 1.65 | 65.9 | Adjuvant (A) | 2017-12-01 | 2017-12-01 | null | 02 | N | PALBOCICLIB | 100944278 |
| 210003431 | 210010588 | 1.65 | 78.4 | null | 2020-02-05 | 2020-02-13 | ROSCO Trial | 02 | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100614570 |
| 210003432 | 210010589 | 1.58 | 104 | Palliative (P) | 2020-04-03 | 2021-11-08 | Capecitabine | 02 | N | CAPECITABINE | 101833996 |
| 210003433 | 210010590 | 1.65 | 49.8 | Neo-adjuvant (N) | null | 2015-10-25 | null | 02 | N | EVEROLIMUS + EXEMESTANE | 101385512 |
| 210003434 | 210010591 | 1.65 | 50.2 | null | 2021-11-18 | 2022-02-11 | Palbociclib | null | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100341751 |
| 210003435 | 210010592 | 1.58 | 86.7 | Neo-adjuvant (N) | 2019-11-27 | 2020-04-10 | Eribulin | 02 | N | ERIBULIN | 101535177 |
| 210003445 | 210010600 | 1.6 | 72.8 | Neo-adjuvant (N) | 2018-08-27 | 2018-09-01 | Epirubicin (weekly) | 02 | N | ABEMACICLIB + FULVESTRANT | 101866837 |
| 210003449 | 210010602 | 1.6 | 72.95 | null | null | 2021-01-17 | Capecitabine | 02 | null | CAPECITABINE | 100247069 |
| 210003450 | 210010603 | null | 91.3 | Palliative (P) | 2020-12-12 | 2020-12-16 | ROSCO Trial | null | N | PACLITAXEL + TRASTUZUMAB | 101074406 |
| 210003452 | 210010605 | 1.68 | 56.55 | 03 | null | 2017-05-31 | EC | null | N | EC | 101775997 |
| 210003454 | 210010606 | 1.57 | 72.6 | Adjuvant (A) | 2013-08-24 | 2017-09-14 | Carboplatin + Docetaxel | 02 | N | PALBOCICLIB | 100587177 |
| 210003460 | 210010608 | 1.58 | null | null | 2019-02-21 | 2019-03-11 | Trastuzumab(Kadcyla®) (Maintenance) | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101755372 |
| 210003462 | 210010609 | null | null | null | 2017-09-08 | 2017-09-21 | null | N | null | LETROZOLE + PALBOCICLIB | 100074478 |
| 210003463 | 210010610 | null | 49.7 | Neo-adjuvant (N) | 2021-06-30 | 2021-09-25 | Talazoparib | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100494571 |
| 210003464 | 210010611 | 1.56 | 0 | Neo-adjuvant (N) | 2018-07-04 | 2018-07-21 | Trastuzumab emtansine (Kadcyla) M | 02 | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 101854779 |
| 210003466 | 210010612 | 1.68 | 56.2 | null | 2021-08-22 | 2021-10-09 | null | 02 | null | EC | 100042368 |
| 210003471 | 210010616 | 1.55 | 68.1 | Adjuvant (A) | 2018-07-12 | 2018-07-13 | null | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100558104 |
| 210003474 | 210010619 | 1.58 | 95 | Neo-adjuvant (N) | null | 2021-11-28 | Capecitabine | 02 | N | CAPECITABINE | 101783446 |
| 210003478 | 210010620 | 1.58 | 59.1 | Curative (C) | 2016-03-15 | 2016-03-27 | Carboplatin AUC 6 - 10 | 02 | N | CARBOPLATIN | 100612533 |
| 210003481 | 210010621 | 1.63 | 61.6 | Palliative (P) | 2022-01-26 | 2022-04-17 | null | 02 | N | TRIAL UNSPECIFIED | 101133255 |
| 210003488 | 210010626 | 1.62 | 69.7 | Palliative (P) | 2018-05-02 | 2018-09-26 | FEC 100 | 02 | N | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 100619331 |
| 210003489 | 210010627 | 1.69 | 96.7 | null | 2017-07-28 | 2017-10-27 | Cyclophosphamide + Docetaxel | 02 | null | EC | 101375288 |
| 210003491 | 210010629 | 1.64 | null | Palliative (P) | 2020-07-17 | 2020-07-24 | null | null | null | FEC | 100591677 |
| 210003501 | 210010633 | 1.66 | 65 | null | 2016-05-20 | 2016-10-10 | Palbociclib | 02 | null | TRIAL UNSPECIFIED | 101043228 |
| 210003502 | 210010634 | 1.63 | 72 | null | 2018-06-18 | 2018-07-08 | FEC 100 | 02 | null | FEC | 100410458 |
| 210003503 | 210010635 | 1.62 | 62.05 | Neo-adjuvant (N) | 2017-05-09 | 2017-05-21 | FEC | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 101800823 |
| 210003504 | 210010636 | 1.55 | 72.3 | Palliative (P) | 2018-02-11 | 2018-03-23 | null | 02 | N | TRIAL UNSPECIFIED | 101572966 |
| 210003508 | 210010638 | 1.48 | 53.9 | Palliative (P) | 2018-07-31 | 2018-08-02 | Neratinib | 02 | N | NERATINIB | 101369033 |
| 210003512 | 210010640 | 1.75 | 90.1 | Adjuvant (A) | 2017-08-25 | 2017-09-08 | EC | 02 | N | EC | 101860377 |
| 210003515 | 210010642 | 1.57 | 69.6 | Neo-adjuvant (N) | 2018-09-27 | 2018-09-27 | null | 02 | N | LETROZOLE + PALBOCICLIB | 100708990 |
| 210003520 | 210010644 | null | 74 | null | 2019-03-03 | 2019-06-02 | null | 02 | null | CAPECITABINE + PERTUZUMAB + TRASTUZUMAB | 100733045 |